Bayer/ONXX—FDA grants priority review for Stivarga in GIST: http://finance.yahoo.com/news/bayers-stivarga-regorafenib-tablets-drug-150300408.html Stivarga was FDA-approved for metastatic CRC a few weeks ago (#msg-79989122).